澳大利亚细胞和基因治疗（CAGT）产品的临床开发

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - Australia is recognized for its mature R&D ecosystem, established regulatory pathways, and cost-effective clinical trial environment for Cell and Gene Therapy (CAGT) products [4][5][6] - The country has over 160 ongoing industry CAGT trials, with a focus on oncology, autoimmune diseases, and cardiovascular conditions [9][12] - IQVIA is highlighted as a leading Contract Research Organization (CRO) in Australia, providing comprehensive support for CAGT products from pre-clinical to post-marketing stages [24][29] Summary by Sections Why Australia for CAGT Trials? - Australia offers a cost-effective and mature clinical research infrastructure, with high-quality data accepted by global regulators [5][6] - The regulatory framework allows for rapid trial initiation and approvals, with minimal documentation required [7][11] - The favorable AUD exchange rate and R&D tax incentives contribute to lower trial costs compared to the U.S. [7] Mature R&D Ecosystem - Australia hosts over 160 ongoing CAGT trials, with a robust clinical research infrastructure and experienced investigators [9][11] - The country has established treatment centers for complex therapies, including CAR-T, and offers end-to-end support from CDMO partners [10][11] Established and Favorable Regulatory Pathway - The Clinical Trial Notification (CTN) process allows for a fast regulatory start-up, typically taking around 7 to 10 days [14][17] - The Therapeutic Goods Administration (TGA) does not evaluate clinical trial data under the CTN scheme, focusing instead on product safety [18] IQVIA, the Leading CRO in Australia - IQVIA provides a local presence with global capabilities, supporting CAGT trials through a network of sites and a dedicated study management team [26][28] - The organization has participated in the clinical development of 17 approved CAGT products, showcasing its expertise in the field [33] Global Reach and Local Impact - IQVIA's capabilities allow for seamless integration of new countries into multi-regional development plans for CAGT products [26][30] - The company offers a comprehensive strategy for commercialization, policy shaping, and stakeholder engagement [29]